SAN DIEGO (AP) — SAN DIEGO (AP) — Cardiff Oncology, Inc. (CRDF) on Tuesday reported a loss of $7.2 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 11 cents.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
The molecular diagnostic company posted revenue of $243,000 in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $130,000.
For the year, the company reported a loss of $45.9 million, or 69 cents per share. Revenue was reported as $593,000.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRDF at https://www.zacks.com/ap/CRDF
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/Amazon_com%20Inc_%20storefront%20by-%20%20Markus%20Mainka%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)